Hirtle Callaghan & Co’s MaxLinear MXL Stock Holding History

Hirtle Callaghan & Co’s Portfolio MXL Stock Details MXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7,956	Closed	-$270K	–	125
2022 Q2	$270K	Sell	7,956 -3,430	-30%	-$144K	0.02%	110
2022 Q1	$664K	Buy	11,386 +7,185	+171%	+$437K	0.03%	76
2021 Q4	$317K	Buy	+4,201	New	+$269K	0.02%	76

Other funds holding MXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

CCM

Channing Capital Management Chicago, Illinois $4.34B AUM 37.08% 1-Year Est. Return

Hirtle Callaghan & Co's MXL Position: Q3 2022 in Review

Hirtle Callaghan & Co sold out of MaxLinear (MXL) in Q3 2022, closing a stake of 7,956 shares — an estimated $270K sold.

Hirtle Callaghan & Co first reported a position in MXL in Q4 2021 and held it in 3 quarters. The position peaked at $664K in Q1 2022. 279 funds tracked by Wall St. Rank hold MXL as of Q3 2022.

Hirtle Callaghan & Co reported no remaining MaxLinear position as of Q3 2022 after selling out during the quarter.
Hirtle Callaghan & Co sold 7,956 MaxLinear shares in Q3 2022, an estimated $270K.
Hirtle Callaghan & Co first reported a position in MaxLinear in Q4 2021 and held it in 3 quarters.
Hirtle Callaghan & Co's MaxLinear position peaked at $664K in Q1 2022.
279 funds tracked by Wall St. Rank held MaxLinear as of Q3 2022.

Based on Hirtle Callaghan & Co's 13F filing for Q3 2022, filed 14 Nov 2022.